FDA Grants Fast Track Designation to Varsetatug Masetecan for Metastatic Colorectal Cancer

The FDA has granted fast track designation to varsetatug masetecan (Varseta-M; CX-2051), an investigational antibody-drug conjugate (ADC), for patients with relapsed or refractory metastatic colorectal cancer (mCRC). The designation follows phase 1 findings that demonstrated antitumor activity in a heavily pretreated population.¹

Varsetatug masetecan is a potential first-in-class ADC directed against epithelial cell adhesion molecule (EpCAM). It carries a topoisomerase 1 inhibitor payload and uses a conditionally activated design intended to concentrate its activity within the tumor microenvironment.¹ CytomX Therapeutics plans to initiate a potentially registrational monotherapy study during the first half of 2027.

Addressing a Difficult Target in Colorectal Cancer

EpCAM is broadly expressed in colorectal tumors, making it an attractive therapeutic target. Its presence on healthy epithelial tissue, however, has historically limited the ability to target it without causing unacceptable toxicity. Varsetatug masetecan was developed using a masking technology designed to reduce binding in healthy tissue. Proteases found in the tumor microenvironment cleave the mask, allowing the ADC to bind EpCAM and deliver its cytotoxic payload near malignant cells.¹˒²

The approach could broaden the therapeutic window for EpCAM-directed treatment, although its clinical benefit and optimal dosing require confirmation in larger studies.

The need for additional later-line options remains substantial. The 5-year relative survival rate is approximately 13% for distant-stage colon cancer and 18% for distant-stage rectal cancer.³ Treatment selection in the metastatic setting depends on previous therapy, tumor molecular characteristics, disease distribution, and patient fitness. Once disease progresses through established regimens, response rates with available later-line treatments are generally low.

Phase 1 Findings Demonstrate Antitumor Activity

The first-in-human CTMX-2051-101 trial (NCT06265688) is evaluating varsetatug masetecan alone and in combination regimens among patients with advanced solid tumors.⁴ Dose escalation began in April 2024, followed by dose-expansion cohorts in mCRC.

At the January 16, 2026, data cutoff, 93 patients with late-line mCRC had enrolled. Participants had received a median of 3 prior treatment lines in the metastatic setting. Most had received irinotecan, whereas 76% had liver metastases and 71% had KRAS-mutated disease. Enrollment did not require a prespecified EpCAM expression level.²

Among 56 efficacy-evaluable patients treated with expansion doses of 7.2 mg/kg, 8.6 mg/kg, or 10 mg/kg every 3 weeks, the confirmed overall response rates were 6%, 20%, and 32%, respectively. Median progression-free survival was 5.5 months with 7.2 mg/kg, 6.8 months with 8.6 mg/kg, and 7.1 months with 10 mg/kg. The disease control rate across the 3 expansion cohorts was 88%.²

CytomX prioritized the 8.6-mg/kg and 10-mg/kg doses for continued optimization. These findings are encouraging for a late-line population, but they come from a nonrandomized early-phase trial with small cohorts. Comparisons with existing therapies should therefore be interpreted cautiously.

Safety and Pharmacy Considerations

Most treatment-related adverse events (TRAEs) reported in the phase 1 study were grade 1 or 2. Diarrhea was the most common TRAE, followed by nausea, fatigue, vomiting, hypokalemia, and anemia. No cases of interstitial lung disease, febrile neutropenia, or pancreatitis were reported as of the cutoff.²

Diarrhea represents a central monitoring consideration. Investigators implemented prophylaxis with an antimotility medication plus budesonide during dose optimization. Among 20 patients receiving this approach at 8.6 mg/kg or 10 mg/kg, the grade 3 diarrhea rate was 10%. Serious TRAEs reported in more than 1 patient included diarrhea, vomiting, hypokalemia, dehydration, acute kidney injury, and colitis.²

If development advances, oncology pharmacists could play an important role in prophylaxis education, early symptom assessment, and supportive-care management. Fluid status, renal function, and electrolytes may warrant close monitoring when gastrointestinal toxicity develops.

Fast Track Status Supports Continued Development

The FDA’s fast track program is intended for investigational therapies that treat serious conditions and demonstrate the potential to address an unmet medical need. The designation permits more frequent communication with the agency and can provide eligibility for rolling review if applicable requirements are met.⁵ It does not constitute FDA approval or confirm clinical efficacy.

CytomX is also evaluating varsetatug masetecan with bevacizumab and plans further combination development with chemotherapy. Updated phase 1 results and the design of the proposed registrational study will help determine whether the early response signal translates into durable benefit for patients with treatment-resistant mCRC.

References

1. CytomX Therapeutics announces FDA Fast Track designation for varsetatug masetecan (“Varseta-M”) for relapsed/refractory metastatic colorectal cancer. News release. CytomX Therapeutics. August 27, 2026. Accessed August 27, 2026. https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-fda-fast-track-designation

2. CytomX’s varsetatug masetecan (EpCAM PROBODY ADC) continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer. News release. CytomX Therapeutics. March 16, 2026. Accessed August 27, 2026. https://ir.cytomx.com/news-releases/news-release-details/cytomxs-varsetatug-masetecan-epcam-probodyr-adc-continues

3. Survival rates for colorectal cancer. American Cancer Society. Updated January 13, 2026. Accessed August 27, 2026. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html

4. First in human study of CX-2051 in advanced solid tumors. ClinicalTrials.gov. Updated July 15th, 2026. Accessed August 27, 2026. https://clinicaltrials.gov/study/NCT06265688

5. Fast Track. FDA. Updated August 13, 2024. Accessed August 27, 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track